Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference26 articles.
1. Gotfrit J, Jackson A, Shin JJW, Stewart DJ, Mallick R, Wheatley-Price P. Determinants of the cancer drug funding process in Canada. Curr Oncol. 2022;29:1997–2007.
2. Liden D, Jaksa A, Daniel K, Ho Y. CADTH recommendations as predictors for drug availability in British Columbia and Ontario. Value Health. 2014;17:A6.
3. Binder L, Ghadban M, Sit C, Barnard K. Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations. Curr Oncol. 2022;29:1514–26.
4. Raymakers AJN, Jenei KM, Regier DA, Burgess MM, Peacock SJ. Early-phase clinical trials and reimbursement submissions to the Pan-Canadian Oncology Drug Review. Pharmacoeconomics. 2021;39:373–7.
5. CADTH. Procedures for CADTH reimbursement reviews; 2022. https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Drug_Reimbursement_Review_Procedures.pdf. Accessed 26 Dec 2022.